Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02227251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 35 words Study description revised · Study sites revised (175) Show 2 more changesShow less
    • Study description revised
    • Study sites revised (175)
  2. Re-verified, no change to tracked fieldsv64
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 176 to 175 · Primary completion date: Apr 2027 to Dec 2026 · Completion date: Nov 2027 to Dec 2026v63 Show 3 more changesShow less
    • Study sites: 176 to 175
    • Primary completion date: Apr 2027 to Dec 2026
    • Completion date: Nov 2027 to Dec 2026
  4. Site details revised at 1 of 176 sitesv62
  5. Site contacts updated at 1 of 176 sitesv61
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 2 of 176 sitesv60
  2. Site details revised at 4 of 176 sitesv59
  3. Study sites: 178 to 176v58
  4. Site contacts updated at 2 of 178 sitesv57
  5. Site contacts updated at 1 of 178 sitesv56
  6. Site details revised at 1 of 178 sitesv55
  7. Primary completion date: Aug 2022 to Apr 2027 Completion date: Dec 2024 to Nov 2027v54 Show 1 more changeShow less
    • Completion date: Dec 2024 to Nov 2027
  8. Site details revised at 2 of 178 sitesv53
  9. Site details revised at 1 of 178 sitesv52
  10. Site details revised at 3 of 178 sitesv51
  11. Site details revised at 1 of 178 sitesv50
  12. Site details revised at 3 of 178 sitesv49
  13. Study sites: 179 to 178v48
  14. Site details revised at 1 of 179 sitesv47
  15. Site details revised at 2 of 179 sitesv46
  16. Trial status: Active, Not Recruiting to Recruiting Site details revised at 179 of 179 sitesv45 Show 1 more changeShow less
    • Site details revised at 179 of 179 sites
  17. Re-verified, no change to tracked fieldsv44
  18. Study sites: 182 to 179v43
  19. Enrollment target: 129 to 244 Primary completion date: Jun 2020 to Aug 2022 · Study sites: 151 to 182 · Completion date: Dec 2020 to Dec 2024 · 5 morev42 Show 8 more changesShow less
    • Primary completion date: Jun 2020 to Aug 2022
    • Study sites: 151 to 182
    • Completion date: Dec 2020 to Dec 2024
    • Interventions: Selinexor (Drug) to Selinexor (Drug), Selinexor (Drug), Selinexor (Drug)
    • Eligibility criteria expanded, about 1,161 words
    • Study description expanded, about 85 words
    • Study title shortened, about 6 words
    • Study arms: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  20. 6 versions Re-verified since Jul 19, 2019, no change to tracked fieldsv36-v41
  21. Primary completion date: Jun 2019 to Jun 2020 Completion date: Aug 2019 to Dec 2020v35 Show 1 more changeShow less
    • Completion date: Aug 2019 to Dec 2020
  22. Study sites: 154 to 151 Primary completion date: Dec 2018 to Jun 2019v34 Show 1 more changeShow less
    • Primary completion date: Dec 2018 to Jun 2019
  23. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 130 to confirmed 129 · Study sites: 177 to 154 · Primary completion date: Nov 2018 to Dec 2018 · 2 morev33 Show 5 more changesShow less
    • Enrollment target: estimated 130 to confirmed 129
    • Study sites: 177 to 154
    • Primary completion date: Nov 2018 to Dec 2018
    • Eligibility criteria revised
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  24. Study sites: 175 to 177v32
  25. Study sites: 171 to 175v31
  26. Study sites: 168 to 171v30
  27. Site details revised at 13 of 168 sitesv29
  28. Study sites: 144 to 168v28
  29. Study sites: 142 to 144v27
  30. Primary completion date: Mar 2018 to Nov 2018 Study sites: 130 to 142 · Completion date: Sep 2018 to Aug 2019v26 Show 2 more changesShow less
    • Study sites: 130 to 142
    • Completion date: Sep 2018 to Aug 2019
  31. Eligibility criteria expanded, about 1 wordv25 See this version in full on ClinicalTrials.gov ↗
  32. Enrollment target: 200 to 130 Primary completion date: Dec 2017 to Mar 2018 · Completion date: Jul 2018 to Sep 2018 · Eligibility criteria expanded, about 28 words · 2 morev24 Show 5 more changesShow less
    • Primary completion date: Dec 2017 to Mar 2018
    • Completion date: Jul 2018 to Sep 2018
    • Eligibility criteria expanded, about 28 words
    • Study description shortened, about 37 words
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  33. Primary completion date: Dec 2016 to Dec 2017 Completion date: Jul 2017 to Jul 2018 · Site details revised at 23 of 130 sitesv23 Show 2 more changesShow less
    • Completion date: Jul 2017 to Jul 2018
    • Site details revised at 23 of 130 sites
  34. Site details revised at 52 of 130 sitesv22
  35. Study sites: 96 to 130v21
  36. Study sites: 92 to 96v20
  37. Primary completion date: Jul 2016 to Dec 2016 Completion date: Dec 2016 to Jul 2017 · Site details revised at 2 of 92 sitesv19 Show 2 more changesShow less
    • Completion date: Dec 2016 to Jul 2017
    • Site details revised at 2 of 92 sites
  38. Site details revised at 5 of 92 sitesv18
  39. Site details revised at 11 of 92 sitesv17
  40. Study Status, Eligibility, Contacts/Locationsv16
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Trial Details
NCT Number NCT02227251
Lead Sponsor Karyopharm Therapeutics Inc
Conditions Diffuse Large B-cell Lymphoma
Enrollment 244 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov